Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor

Distinct RanBP1 nuclear export and cargo dissociation mechanisms between fungi and animals

(2019) Yuling Li et al.   eLife

Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications

(2018) Christopher D. Spicer et al.   CHEMICAL SOCIETY REVIEWS

Engineering functional inorganic–organic hybrid systems: advances in siRNA therapeutics

(2018) Jianliang Shen et al.   CHEMICAL SOCIETY REVIEWS

Nanoparticle drug delivery systems: an excellent carrier for tumor peptide vaccines

(2018) Jiemin Wang et al.   DRUG DELIVERY

Correlation of CRM1-NES affinity with nuclear export activity

(2018) Szu-Chin Fu et al.   MOLECULAR BIOLOGY OF THE CELL

Alnylam launches era of RNAi drugs

(2018) Ken Garber   NATURE BIOTECHNOLOGY

Peptidomimetics Targeting Protein-Protein Interactions for Therapeutic Development

(2018) Gan Zhang et al.   PROTEIN AND PEPTIDE LETTERS

In silico structure-based approaches to discover protein-protein interaction-targeting drugs

(2017) Woong-Hee Shin et al.   METHODS

Landmark gene therapy poised for US approval

(2017) Chris Morrison   NATURE REVIEWS DRUG DISCOVERY

Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals

(2017) Ho Yee Joyce Fung et al.   eLife

CRM1 Inhibitors for Antiviral Therapy

(2017) Cynthia Mathew et al.   Frontiers in Microbiology

Targeting nuclear transporters in cancer: Diagnostic, prognostic and therapeutic potential

(2016) Tamara Stelma et al.   IUBMB LIFE

Nanotechnology for protein delivery: Overview and perspectives

(2016) Mikyung Yu et al.   JOURNAL OF CONTROLLED RELEASE

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

(2016) Z A Hing et al.   LEUKEMIA

The coming of age of de novo protein design

(2016) Po-Ssu Huang et al.   NATURE

MutaBind estimates and interprets the effects of sequence variants on protein–protein interactions

(2016) Minghui Li et al.   NUCLEIC ACIDS RESEARCH

Automatic crystal centring procedure at the SSRF macromolecular crystallography beamline

(2016) Zhijun Wang et al.   JOURNAL OF SYNCHROTRON RADIATION

LNA aptamer based multi-modal, Fe 3 O 4 -saturated lactoferrin (Fe 3 O 4 -bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging

(2015) Kislay Roy et al.   BIOMATERIALS

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance

(2015) J. S. Khorashad et al.   BLOOD

Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells

(2015) Mingshan Niu et al.   CANCER BIOLOGY & THERAPY

Role of Nanotechnology in Delivery of Protein and Peptide Drugs

(2015) Sushilkumar Patil et al.   CURRENT PHARMACEUTICAL DESIGN

High-precision, automated integration of multiple isothermal titration calorimetric thermograms: New features of NITPIC

(2015) Thomas H. Scheuermann et al.   METHODS

Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein

(2015) Jo Ishizawa et al.   PHARMACOLOGY & THERAPEUTICS

Clinical translation of nuclear export inhibitors in cancer

(2014) William T. Senapedis et al.   SEMINARS IN CANCER BIOLOGY

In vivo Gold Nanoparticle Delivery of Peptide Vaccine Induces Anti-Tumor Immune Response in Prophylactic and Therapeutic Tumor Models

(2014) Joao Paulo Mattos Almeida et al.   Small

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Structural basis for cooperativity of CRM1 export complex formation

(2013) T. Monecke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1

(2013) Qingxiang Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

(2011) K. Sakakibara et al.   BLOOD

NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1

(2010) Thomas Güttler et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structural basis for leucine-rich nuclear export signal recognition by CRM1

(2009) Xiuhua Dong et al.   NATURE

A Supraphysiological Nuclear Export Signal Is Required for Parvovirus Nuclear Export

(2008) Dieuwke Engelsma et al.   MOLECULAR BIOLOGY OF THE CELL